16 March 2022
Glossary
Members, abbreviations, and key terms we use to discuss leprosy.
Members, abbreviations, and key terms we use to discuss leprosy.
ALM: American Leprosy Missions
FELEHANSEN: Federation of organisations of people affected by Hansen’s disease
IDEA: International Association for Integration, Dignity and Economic Advancement
ILA: International Leprosy Association
ILEP: International Federation of Anti-Leprosy NGOs
LRI: Leprosy Research Initiative
MORHAN: Movimento de Reintegração das Pessoas Atingidas pela Hanseníase (Movement of Reintegration of Persons Afflicted by Hansen’s disease)
NLR: Netherlands Leprosy Relief
NNN: Neglected Tropical Disease NGO Network
SHF: Sasakawa Health Foundation
TLM: The Leprosy Mission International
TLMTI: The Leprosy Mission Trust India
WHO: World Health Organisation
WHO GLP: World Health Organisation Global Leprosy Program
ADR: adverse drug reaction
CBR: community-based rehabilitation
G0D: grade-0 disability
G1D: grade-1 disability
G2D: grade-2 disability
IEC: information, education, communication
LPEP: Leprosy Post-Exposure Prophylaxis Programme
LT: GPZL’s Leadership Team
MB: multibacillary
MDA: mass drug administration
MDT: multidrug therapy
M. leprae: Mycobacterium leprae
NCDR: new case detection rate
NLP: National Leprosy Programme
NLPM: National Leprosy Programme Manager
NTD: neglected tropical disease
PB: paucibacillary
PEP: post-exposure prophylaxis
ROM: rifampicin, ofloxacin, minocycline
SHG: self-help group
SDR: single-dose rifampicin
bacillus: a rod-shaped bacterium
best practice: a recommended practice based on current evidence
blanket approach: a strategy where the entire population of a defined geographic area is provided with a prophylactic drug
case: a person undergoing treatment for leprosy
chemoprophylaxis: the use of a drug to prevent clinical disease in apparently healthy people
COLEP study: a randomized controlled trial conducted from 2002 to 2007 in Bangladesh that resulted in influential research on evidence for SDR-PEP
communicable disease: a contagious disease that is transmissible from person to person or from animal to person; leprosy is a communicable disease
community-based rehabilitation (CBR): community initiatives to enhance the quality of life in patients with disabilities
contact: a person living in proximity to a leprosy patient for a prolonged duration
contact approach: a strategy where only the patient’s household members and social contacts identified by contact tracing are provided with a prophylactic
contact management: the identification of people who have been exposed to an index case, counselling, provision of information on risk and early signs of leprosy, examination to exclude current disease, and provision of chemoprophylaxis where appropriate
contact tracing: the process of identifying and examining people who have been exposed to a disease to prevent transmission
counselling: the interaction between two individuals to solve the problem of one of the individuals; an ethical requirement in contact tracing and PEP implementation
country partner: a country that works with GPZL
dapsone hypersensitivity syndrome: a rare and serious adverse drug reaction (ADR) to the dapsone component of multi-drug therapy (MDT); experienced by about 1% of leprosy patients
disability: a social process that results from the interaction between persons with impairments and the attitudes and environmental barriers that prevent their equal participation in society
discrimination: an action, inaction, or behaviour resulting in negative, differential treatment of an individual or a group
elimination of leprosy as a public health problem: reduction in cases of a disease, as defined by the World Health Organization (WHO), to less than one case per 10,000 people across a larger population
eradication: zero incidences of infection within a defined geographic area; leprosy is not yet eradicated globally
Global Partnership for Zero Leprosy (GPZL, the Partnership): a coalition of people committed to ending leprosy, also known as Hansen’s disease
grade-0 disability (G0D): disability characterized by no visible damage, no loss of protective sensation, and no eye problems
grade-1 disability (G1D): disability characterized by loss of protective sensation or eye problems; no visual impairment
grade-2 disability (G2D): disability characterized by visible damage or severe visual impairment
Hansen’s disease (HD): the medical term for leprosy, named after Gerhard Henrik Armauer Hansen, the Norwegian doctor who discovered Mycobacterium leprae, which causes leprosy
healthcare: a system or industry that facilitates health care
health care: a provider’s efforts to maintain a patient’s physical, emotional, and mental wellbeing
hypopigmentation: pale or reddish skin patches that can be symptomatic of leprosy
incubation period: time elapsed between exposure to a pathogen and when symptoms first appear; the incubation period for leprosy is 2 to 10 years.
index case: the first documented patient in a disease epidemic within a household or population
immunoprophylaxis: protection against infectious diseases by producing active or passive immunity
Leadership Team (LT): the board that provides strategic direction, oversight and guidance for GPZL
leprosy (also, Hansen’s disease): a curable infection that affects the skin, eyes, nose, and peripheral nerves; it is caused by Mycobacterium leprae and transmitted via droplets through the nose and mouth of untreated patients
leprosy burden: the prevalence of the disease, 80% of which falls in three countries: India, Brazil, and Indonesia
Leprosy Post-exposure Prophylaxis (LPEP): a long-term study on operationalizing SDR-PEP conducted in 8 countries
mass drug administration (MDA): large-scale access to preventative medicine
member: an organization or individual affiliate who joins GPZL
multibacillary (MB): a classification of leprosy associated with multiple (more than five) skin lesions, nodules, plaques, thickened dermis, or skin infiltration
multi-drug therapy (MDT): a combination of three antibiotic drugs (dapsone, rifampicin, and clofazimine) recommended by the World Health Organization (WHO) that effectively kills the pathogen and cures a leprosy patient
Mycobacterium leprae (M. leprae): the bacterium that causes leprosy
National Leprosy Programme (NLP): an in-country leprosy programme that partners with GPZL
National Leprosy Programme Managers (NLPMs): the directors of in-country programmes that partner with GPZL
natural immunity: 95% of people do not contract leprosy if exposed due to natural immunity
neglected tropical diseases (NTDs): viral, parasitic, and bacterial communicable diseases prevalent in tropical and subtropical climates; NTDs disproportionately affect vulnerable communities
neuropathic pain: burning or shooting pain associated with nerve injury due to leprosy
non-communicable disease: a disease that is not transmissible directly from one person to another
paucibacillary (PB): a milder classification of leprosy characterized by a few skin lesions
person(s) affected by leprosy: individuals who experience leprosy directly or as family members, friends, and community members of people diagnosed with leprosy
post-exposure prophylaxis (PEP): Administration of drugs (e.g. rifampicin) or vaccines to prevent disease in a person after exposure to a leprosy patient
prophylaxis: administration of a drug or vaccine to prevent disease
PEP++ project: a study that is underway to test a regimen of multiple antibiotics and a longer duration of doses to further reduce the risk of contraction by close contacts, and to test blanket approaches
rifampicin: an antibiotic used to treat bacterial infections
Secretariat: the staff that manages the Partnership’s daily operations, communications, and resource mobilization efforts; located a the Task Force for Global Health
self-help group (SHG) (also, self-care group): a community of persons affected who share strategies and tools for self-care and support one another’s commitment to physical and mental wellbeing
self-screening approach: a strategy where materials showing symptoms and signs are distributed for contacts to self-examine and report to a health facility
single-dose rifampicin (SDR): used as post-exposure prophylaxis (PEP) for contacts of leprosy patients to prevent transmission
skin camp: a temporary, community-wide event that provides examination and treatment of skin diseases
skin camp approach: a strategy where skin camps are organized in an endemic area to detect leprosy cases and treat skin diseases
special rapporteur: an independent expert working on behalf of the United Nations within the scope of a thematic mandate from the United Nations Human Rights Council
stigma: labelling and discrimination against a person or group of people by marking them as socially unacceptable; a barrier to ending transmission
toolkit: practical resources and best practices for programme managers
working group: a small team of researchers, persons affected, and programmatic experts that leads action to protect leprosy prevention and control gains, to support persons affected, and to set a path toward zero leprosy
Working Group: the title of a specific working group (e.g., Emergency Advocacy Working Group)
Zero Leprosy Country Model: country-led customized strategies that address local needs and priorities to end leprosy executed by National Leprosy Programmes, GPZL’s in-country partners, and international stakeholders
Zero Leprosy Toolkit: a set of field-tested best practices designed to support countries in their work towards ending leprosy and its associated disabilities and stigma